本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025年9月15日 (二)股东大会召开的地点：四川省成都市锦江区三色路427号公司办公楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，股东大会主持情况等。 1、公司在任董事9人，出席9人；其中3人为公司独立董事； 2、董事会秘书出席本次会议；其他高管列席了本次会议。 二、议案审议情况 (一)非累积投票议案 1、议案名称：关于对外投资涉及关联交易的议案 审议结果：通过 表决情况： ■ 本次股东大会由董事长陈达彬先生主持，大会的表决方式符合《公司法》及《公司章程》的规定。 (五)公司董事和董事会秘书的出席情况 三、律师见证情况 1、本次股东大会见证的律师事务所：泰和泰律师事务所 律师：谭蕾、刘化勇 2、律师见证结论意见： 公司2025年第二次临时股东大会的召集、召开程序、召集人的资格、出席本次股东 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of September 15, 2025 [1] Core Insights - The trend of Chinese innovative drugs going overseas continues, with a focus on selective opportunities. The report highlights that the global pharmaceutical transaction volume reached 456 deals in the first half of 2025, a 32% year-on-year increase, with upfront payments totaling $11.8 billion, a 136% surge, and total transaction value hitting $130.4 billion, up 58% year-on-year [2] - The report emphasizes the promising clinical data from Chinese innovative drugs presented at the World Lung Cancer Conference, particularly in the ADC (Antibody-Drug Conjugate) field, showcasing significant efficacy advantages [3] - The report discusses the potential of small nucleic acid drugs and innovative delivery systems, indicating new market opportunities arising from strategic collaborations between Chinese companies and multinational corporations [4] - The CXO (Contract Research Organization) sector is expected to gradually recover, with a notable increase in orders anticipated in the third quarter of 2025, driven by improved innovation environments and funding from license-out transactions [5] - The 2025 medical insurance negotiation and commercial insurance innovative drug directory work has commenced, with a focus on orphan drugs and breakthrough treatment varieties [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry underperformed the CSI 300 index by 1.75% in the past week, with a recent one-month increase of 3.32%, lagging behind the CSI 300 by 5.81% [22][26] - The medical device sector showed the highest weekly increase of 2.23%, while the chemical pharmaceutical sector experienced a decline of 2.57% [31] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index's current PE (TTM) stands at 40.60, above the five-year historical average of 31.60 [46] - The report notes that the pharmaceutical sector has shown a 15.06% increase over the past three months, outperforming the CSI 300 by 16.11% [43] 3. Recent Research Achievements - The report outlines recent research achievements by the Huaxin pharmaceutical team, including various in-depth and commentary reports on innovative drug developments and market trends [50] 4. Recent Industry Policies and News - The report details recent policy updates from the National Healthcare Security Administration regarding the 2025 drug directory adjustments and the approval of new drug applications [52][55]

证券代码：600211 证券简称：西藏药业 公告编号：2025-034 西藏诺迪康药业股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 15 日 (二)股东大会召开的地点：四川省成都市锦江区三色路 427 号公司办公楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 700 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 62,178,322 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 30.7942 | (五)公司董事和董事会秘书的出席情况 1、公司在任董事9人，出席9人；其中 3 人为公司独立董事； 2、董事会秘书出席本次会议；其他高管列席了本次会议。 二、 议案审议情况 (一)非累积投票议案 1、 议案名称：关 ...

泰和泰律师事务所 关于西藏诺迪康药业股份有限公司 2025 年第二次临时股东大会的 f 2025 年 9 月 15 日 中国•成都市天府新区隆和西巷 299 号 泰和泰中心 21—33F 21-33f, Tahota Center, No.299 Longhe West Lane, 泰和泰律师事务所 关于西藏诺迪康药业股份有限公司 2025 年第二次临时股东大会的法律意见书 致:西藏诺迪康药业股份有限公司 散启若 泰和泰律师事务所（以下简称"泰和泰"或"本所"）作为西藏 诺迪康药业股份有限公司（以下简称"西藏药业"或"公司"）的常 年法律顾问,现接受公司的委托. 指派谭蕾、刘化勇律师出席公司 2025 年第二次临时股东大会。并依据《中华人民共和国公司法》（以下简 称"《公司法》"）《上市公司股东大会规则》（以下简称"《股东 大会规则》")《西藏诺迪康药业股份有限公司章程》（以下简称"《公 司章程》")及其他相关法律法规的规定,就公司本次股东大会的召 集、召开程序、召集人资格、出席会议人员的资格、表决程序等有关 事项出具本法律意见书。 本所律师出具法律意见,仅依据本法律意见书出具日以前发生或 者存在的事实,并基 ...

证券之星消息，9月15日生物制品板块较上一交易日下跌0.7%，西藏药业领跌。当日上证指数报收于 3860.5，下跌0.26%。深证成指报收于13005.77，上涨0.63%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301393 | 吴帆生物 | 59.20 | 9.10% | 7.18万 | 4.18亿 | | 603590 | 康辰药业 | 57.81 | 5.24% | 6.44万 | 3.74亿 | | 002581 | ST未名 | 8.39 | 5.01% | 7.75万 | 6377.87万 | | 000534 | 万泽股份 | 16.52 | 3.70% | 21.62万 | 3.54Z | | 688293 | XD奥浦迈 | 53.67 | 2.33% | 2.80万 | 1.52亿 | | 300841 | 康华生物 | 82.22 | 2.14% | 5.40万 | 4.43亿 | | 430047 | 诺思兰德 | 26.39 | ...

Market Overview - The biopharmaceutical sector experienced a slight increase of 0.0% on September 12, with Aopumai leading the gains [1] - The Shanghai Composite Index closed at 3883.69, up by 0.22%, while the Shenzhen Component Index closed at 12996.38, up by 0.13% [1] Top Gainers in Biopharmaceutical Sector - Aopumai (688293) closed at 54.00, with a rise of 4.73% and a trading volume of 20,300 lots, totaling a transaction value of 103 million [1] - Kexing Pharmaceutical (688136) closed at 42.28, increasing by 3.45% with a trading volume of 47,400 lots, amounting to 197 million [1] - Sanofi (688336) closed at 57.07, up by 3.39% with a trading volume of 52,600 lots, totaling 294 million [1] - Tibet Pharmaceutical (600211) closed at 56.60, rising by 3.38% with a trading volume of 93,300 lots, totaling 510 million [1] - Wenqu Pharmaceutical (688488) closed at 16.00, increasing by 2.83% with a trading volume of 86,300 lots, amounting to 134 million [1] Top Decliners in Biopharmaceutical Sector - Rongchang Biopharmaceutical (688331) closed at 107.22, down by 2.68% with a trading volume of 56,400 lots, totaling 611 million [2] - Wanze Shares (000534) closed at 16.02, decreasing by 2.61% with a trading volume of 135,500 lots, amounting to 218 million [2] - Kangtai Biopharmaceutical (300601) closed at 18.63, down by 1.48% with a trading volume of 156,700 lots, totaling 292 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 310 million from institutional investors, while retail investors experienced a net inflow of 132 million [2] - Notable net inflows from retail investors were observed in Kanghua Biological (300841) with 94.86 million, and Xizang Pharmaceutical (600211) with 49.76 million [3] - Conversely, significant net outflows were noted in Rongchang Biopharmaceutical (688331) with 17.13 million and Aopumai (688293) with 18.19 million from retail investors [3]

Core Viewpoint - Xizang Pharmaceutical Co., Ltd. has seen a stock price increase of 5.02%, reaching 57.50 CNY per share, with a trading volume of 633 million CNY and a turnover rate of 3.56%, resulting in a total market capitalization of 18.533 billion CNY [1] Company Overview - Xizang Pharmaceutical Co., Ltd. is located in Lhasa Economic and Technological Development Zone, Tibet, and was established on July 14, 1999, with its listing date on July 21, 1999. The company primarily engages in pharmaceutical manufacturing [1] - The main revenue composition of the company is 99.80% from drug sales and 0.20% from other supplementary sources [1] Shareholder Information - Among the top ten circulating shareholders of Xizang Pharmaceutical, Huaxia Fund's Huaxia Industry Prosperity Mixed Fund (003567) holds 1.9036 million shares, unchanged from the previous period, accounting for 0.59% of circulating shares. The estimated floating profit today is approximately 5.235 million CNY [2] - The Huaxia Industry Prosperity Mixed Fund was established on February 4, 2017, with a latest scale of 7.261 billion CNY. Year-to-date returns are 49.16%, ranking 881 out of 8174 in its category; the one-year return is 99.56%, ranking 463 out of 7981; and since inception, the return is 357.78% [2] Fund Management - The fund manager of Huaxia Industry Prosperity Mixed Fund is Zhong Shuai, who has been in the position for 5 years and 48 days. The total asset scale of the fund is 8.253 billion CNY, with the best fund return during his tenure being 167.61% and the worst being 8.67% [3]

Group 1 - The core viewpoint of the news is that Tibet Pharmaceutical has shown significant stock performance, with a year-to-date increase of 59.29% and a recent 10.66% rise over the last five trading days [1] - As of September 12, the stock price reached 55.86 yuan per share, with a total market capitalization of 18.005 billion yuan [1] - The company primarily engages in pharmaceutical manufacturing, with 99.80% of its revenue coming from drug sales [1] Group 2 - As of June 30, the number of shareholders decreased by 8.08% to 45,200, while the average number of circulating shares per person increased by 8.79% to 7,132 shares [2] - For the first half of 2025, Tibet Pharmaceutical reported a revenue of 1.651 billion yuan, reflecting a year-on-year growth of 2.23%, while the net profit attributable to shareholders decreased by 8.96% to 567 million yuan [2] - The company has distributed a total of 2.258 billion yuan in dividends since its A-share listing, with 1.580 billion yuan distributed over the past three years [3]

Group 1 - The company announced that it will hold the second extraordinary general meeting of shareholders on September 15, 2025 [1] - The agenda for the meeting includes the review of a proposal related to external investment involving connected transactions [1]

Core Insights - The biopharmaceutical sector experienced a 0.64% increase on September 8, with Tibet Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3826.84, up 0.38%, while the Shenzhen Component Index closed at 12666.84, up 0.61% [1] Biopharmaceutical Sector Performance - Tibet Pharmaceutical (600211) saw a closing price of 55.53, with a significant increase of 10.00% and a trading volume of 257,300 shares, amounting to a transaction value of 1.364 billion [1] - Kanghua Biological (300841) closed at 76.38, up 5.35%, with a trading volume of 63,500 shares and a transaction value of 484 million [1] - Sairun Biological (688163) closed at 25.35, up 4.71%, with a trading volume of 19,500 shares and a transaction value of 48.51 million [1] - Other notable performers include Jin Ke (688670) with a 3.35% increase, Mu Li Pharmaceutical (603087) and Wantai Biological (603392) both up 3.18% [1] Decliners in the Biopharmaceutical Sector - Sanofi Guojian (688336) experienced a decline of 6.07%, closing at 57.86, with a trading volume of 116,500 shares and a transaction value of 680 million [2] - Baiao Tai (688177) closed at 32.47, down 2.29%, with a trading volume of 37,900 shares and a transaction value of 124 million [2] - Other companies such as Yuansijinhai (836547) and Nuo Silan De (430047) also saw declines of 2.17% and 1.52% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net inflow of 76.9582 million from institutional investors, while retail investors experienced a net outflow of 56.6098 million [2][3] - Tibet Pharmaceutical had a net inflow of 246 million from institutional investors, while retail investors had a net outflow of 142 million [3] - Kanghua Biological had a net inflow of 49.0462 million from institutional investors, with retail investors experiencing a net outflow of 35.3677 million [3]